Universitatsklinikum Erlangen | Radiation Oncology Department

Research site

(Unclaimed)

Location

Strahlenklinik, Erlangen, Bavaria, Germany

Site insights

Top conditions

Top treatments

AMG 479

Cx601

TAR-200

Ustekinumab

Milvexian

Methoxsalen

BMS-986165

Povorcitinib

Pembrolizumab

Guselkumab

Parent organization

This site is a part of Universitatsklinikum Erlangen

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 24 total trials

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling

Bladder Cancer

Biological: Cetrelimab

Drug: TAR-200

Locations recently updated

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting

HER2 Positive Breast Cancer

Drug: Pertuzumab

Drug: Trastuzumab

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (UNIFI Jr)

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and...

Active, not recruiting

Colitis, Ulcerative

Drug: Matching Placebo

Drug: Ustekinumab Dose Based on BSA and Body Weight

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling

NonSegmental Vitiligo

Drug: Placebo

Drug: Povorcitinib

iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

A prospective, single-arm, multi-center study designed to collect real world safety and performance data of the Adagio Medical iCLAS Cryoablation Sys...

Enrolling

Paroxysmal Atrial Fibrillation

Atrial Flutter

Device: cryoablation procedure using the iCLAS Cryoablation System

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects h...

Active, not recruiting

Triple Negative Breast Neoplasms

Drug: Pembrolizumab

Drug: ladiratuzumab vedotin

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93...

Active, not recruiting

Multiple Myeloma

Drug: CC-93269

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (BIOADAPTOR RCT)

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease...

Active, not recruiting

Coronary Artery Disease

Coronary Artery Stenosis

Device: Percutaneous Coronary Intervention